|
Fascial space
|
HIV + ve n (%)
|
HIV-ve n (%)
|
Female n (%)
|
Male n (%)
|
Outpatient n (%)
|
Inpatient n (%)
|
|---|
|
Buccal
|
14 (6.8)
|
38 (18.5)
|
28 (13.7)
|
24 (11.7)
|
47 (22.9)
|
5 (2.4)
|
|
Submasseteric
|
9 (4.4)
|
37 (18.1)
|
14 (6.8)
|
32 (15.6)
|
38 (18.5)
|
8 (3.9)
|
|
Submandibular
|
14 (6.8)
|
22 (10.7)
|
18 (8.9)
|
18 (8.9)
|
21 (10.2)
|
15 (7.3)
|
|
Temporal
|
4 (2.0)
|
11 (5.4)
|
6 (2.9)
|
9 (4.4)
|
10 (4.9)
|
5 (2.4)
|
|
Canine
|
4 (2.0)
|
9 (4.4)
|
5 (2.4)
|
8 (3.9)
|
12 (5.9)
|
1 (0.5)
|
|
Parapharyngeal
|
5 (2.4)
|
7 (3.4)
|
5 (2.4)
|
7 (3.4)
|
3 (1.5)
|
9 (4.4)
|
|
Pretracheal
|
2 (1.0)
|
4 (2.0)
|
4 (2.0)
|
2 (1.0)
|
0 (0.0)
|
6 (2.9)
|
|
Peritonsillar
|
0 (0.0)
|
5 (2.4)
|
3 (1.5)
|
2 (1.0)
|
4 (2.0)
|
1 (0.5)
|
|
Pterygoid
|
1 (0.5)
|
4 (2.0)
|
2 (1.0)
|
3 (1.5)
|
3 (1.5)
|
2 (1.0)
|
|
Parotid
|
1 (0.5)
|
3 (1.5)
|
4 (2.0)
|
0 (0.0)
|
3 (1.5)
|
1 (0.5)
|
|
Submental
|
0 (0.0)
|
3 (1.5)
|
2 (1.0)
|
1 (0.5)
|
3 (1.5)
|
0 (0.0)
|
|
Sublingual
|
1 (0.5)
|
1 (0.5)
|
0 (0.0)
|
2 (1.0)
|
0 (0.0)
|
2 (1.0)
|
|
Retropharyngeal
|
1 (0.5)
|
1 (0.5)
|
1 (0.5)
|
1 (0.5)
|
0 (0.0)
|
2 (1.0)
|
|
Labial
|
2 (1.0)
|
0 (0.0)
|
2 (1.0)
|
0 (0.0)
|
2 (1.0)
|
0 (0.0)
|
|
Periorbital
|
0 (0.0)
|
2 (1.0)
|
0 (0.0)
|
2 (1.0)
|
2 (1.0)
|
0 (0.0)
|
|
Single
|
18 (14.4)
|
50 (40.0)
|
39 (31.2)
|
29 (23.2)
|
61 (48.8)
|
7 (5.6)
|
|
Multiple
|
16 (12.8)
|
41 (32.8)
|
22 (17.6)
|
35 (28.0)
|
40 (32.0)
|
17 (13.6)
|
- HIV + ve – HIV sero-positive, HIV-ve – HIV sero-positive.
